CompletedPhase 2NCT05569746
A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS
Studying Hemolytic uremic syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Inmunova S.A.
- Principal Investigator
- Fernando Goldbaum, PhDInmunova S.A.
- Intervention
- INM004(drug)
- Enrollment
- 57 enrolled
- Eligibility
- 1-12 years · All sexes
- Timeline
- 2022 – 2023
Study locations (16)
- Hospital Interzonal Dr. José Penna, Bahía Blanca, Buenos Aires, Argentina
- Hospital De Niños Sor María Ludovica, La Plata, Buenos Aires, Argentina
- Hospital Interzonal Especializado Materno Infantil Don Victorio Tetamanti, Mar del Plata, Buenos Aires, Argentina
- Hospital El Cruce - Néstor Kirchner, San Juan Bautista, Buenos Aires, Argentina
- Hospital Dr. Lucio Molas, Santa Rosa, La Pampa Province, Argentina
- Sanatorio de Niños, Rosario, Santa Fe Province, Argentina
- Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina
- Clínica Zabala Swiss Medical, Buenos Aires, Argentina
- Hospital de Pediatría Garrahan, Buenos Aires, Argentina
- Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aire, Argentina
- Hospital de Niños Dr. Ricardo Gutierrez, Ciudad Autonoma de Buenos Aire, Argentina
- Sanatorio Güemes, Ciudad Autonoma de Buenos Aire, Argentina
- Hospital de Niños de la Santísima Trinidad, Córdoba, Argentina
- Sanatorio Allende, Córdoba, Argentina
- Hospital Pediátrico Dr. Humberto Notti, Mendoza, Argentina
- +1 more locations on ClinicalTrials.gov
Collaborators
KLIXAR · Linical Co., Ltd. · PHV LATAM
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05569746 on ClinicalTrials.govOther trials for Hemolytic uremic syndrome
Additional recruiting or active studies for the same condition.